The influence of lipoproteina(a) on cardio-vascular diseases
DOI:
https://doi.org/10.12775/JEHS.2024.54.013Keywords
lipoproteina(a), cardiovascular risk, cardiovascular disease, aortic stenosisAbstract
Introduction
The current evidence from 2022 published by European Atherosclerosis Society brings the importance of the level of lipoprotein(a) and its influence on the human health. Especially atherosclerotic cardio-vascular events such as myocardial infarction, heart failure, stroke, atherosclerosis are taken into account. They prove, that the associations between the level of Lp(a) is linear with the occurrence of cardio-vascular events. High level of Lp(a), may contribute to the aortic stenosis, cause has pro-inflammatory and pro-atherosclerotic properties. The newest finding demonstrate that Lp(a) has no link with venous thrombosis. Nonetheless, very low level of may contribute with type 2 diabetes.
It is recommended to measure the level of lipoprotein(a) at least once in adults to search the patients with higher value than norm. Even at low level of LDL, high Lp(a) is a risk factor for ASCVD. It brings the clinical importance of early detection of potential cardio-vascular diseases and introduction of management. The newest statement form EAS also brings promising possibilities due to specific Lp(a)-lowering therapies is in phase II/III trials.
Aim of the study
The following paper aims to present a review of the current knowledge about the influence of the level of Lp(a) on cardio-vascular disease and seeks to enhance knowledge and promote effective management of this prevalent condition.
The primary goal is to promote the current problem to health care workers with up-to-date information to facilitate early recognition of cardiovascular events.
Materials and methods
This article presents the current state of knowledge of lipoprotein(a) found in various scientific articles.
The following English keywords and its Polish equivalents were used to search Google Scholar's medical databases: lipoprotein(a), cardio-vascular disease, cardiovascular risk, aortic stenosis. The articles most pertinent to the subject have been chosen.
References
https://empendium.com/manualmibe/tratado/chapter/B76.I.B.3.13.
https://pubmed.ncbi.nlm.nih.gov/36007992/
Børge G Nordestgaard i wsp. Lipoprotein(a) as a cardiovascular risk factor: current status.; DOI: 10.1093/eurheartj/ehq386
https://en.wikipedia.org/wiki/Lipoprotein(a)
F Kronenberg , G Utermann. Lipoprotein(a): resurrected by genetics, DOI: 10.1111/j.1365-2796.2012.02592.x
Pia R Kamstrup. Lipoprotein(a) and Cardiovascular Disease DOI: 10.1093/clinchem/hvaa247
Carol A Derby , Sybil L Crawford, Richard C Pasternak, Maryfran Sowers, Barbara Sternfeld, Karen A Matthews Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation DOI: 10.1093/aje/kwp043
Enkhmaa B, Petersen KS , Kris-Etherton PM , Berglund L. Diet and Lp(a): does dietary change modify residual cardiovascular risk conferred by Lp(a)? Nutrients 2020 ;12:2024
Anupam Kotwal Tiffany Cortes, Natalia Genere i wsp. Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis DOI: 10.1210/clinem/dgaa672
S Edén , O Wiklund, J Oscarsson, T Rosén, B A Bengtsson. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations DOI: 10.1161/01.atv.13.2.296
R Zechner, G Desoye, M O Schweditsch, K P Pfeiffer, G M Kostner. Fluctuations of plasma lipoprotein-A concentrations during pregnancy and post partum DOI: 10.1016/0026-0495(86)90150-2
N Sattar , P Clark, I A Greer, J Shepherd, C J Packard. Lipoprotein (a) levels in normal pregnancy and in pregnancy complicated with pre-eclampsia DOI: 10.1016/s0021-9150(99)00296-8
S R Salpeter , J M E Walsh, T M Ormiston, E Greyber, N S Buckley, E E Salpeter. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women DOI: 10.1111/j.1463-1326.2005.00545.x
Florian Kronenberg. Causes and consequences of lipoprotein(a) abnormalities in kidney disease DOI: 10.1007/s10157-013-0875-8
Jemma C Hopewell , Richard Haynes , Colin Baigent. The role of lipoprotein (a) in chronic kidney disease DOI: 10.1194/jlr.R083626
J Feely , M Barry, P W Keeling, D G Weir, T Cooke. Lipoprotein(a) in cirrhosis DOI: 10.1136/bmj.304.6826.545
H G Kraft , H J Menzel, F Hoppichler, W Vogel, G Utermann. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis DOI: 10.1172/JCI113849
Florian Kronenberg i wsp. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
Medycyna praktyczna-
Aniruddh P Patel I wsp. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank doi: 10.1161/ATVBAHA.120.315291. Epub 2020 Oct 29.
Pia R Kamstrup Børge G Nordestgaard. Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population DOI: 10.1016/j.jchf.2015.08.006
Anne Langsted , Pia R Kamstrup , Børge G Nordestgaard. High lipoprotein(a) and high risk of mortality DOI: 10.1093/eurheartj/ehy902
Anne Langsted , Børge G Nordestgaard , Pia R Kamstrup. Elevated Lipoprotein(a) and Risk of Ischemic Stroke DOI: 10.1016/j.jacc.2019.03.524
Sebhat Erqou, Stephen Kaptoge i wsp. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality Emerging Risk Factors Collaboration; DOI: 10.1001/jama.2009.1063
Major adverse cardiovascular events - Wikipedia
Michael B Boffa Saverio Stranges , Neil Klar , Patrick M Moriarty , Gerald F Watts , Marlys L Koschinsky. Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal DOI: 10.1016/j.jacl.2018.08.012
John J Albers, April Slee, i wsp. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes) DOI: 10.1016/j.jacc.2013.06.051
Peter Willeit, Paul M Ridker , Paul J Nestel , i wsp. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. DOI: 10.1016/S0140-6736(18)31652-0
Michelle O’Donoghue, MD MPH David A. Morrow, MD MPH Sotirios Tsimikas, MD Sarah Sloan, i wsp. Lipoprotein (a) For Risk Assessment in Patients with Established Coronary Artery Disease DOI: 10.1016/j.jacc.2013.09.042
Christian M Madsen , Pia R Kamstrup , Anne Langsted , Anette Varbo , Børge G Nordestgaard Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study DOI: 10.1161/ATVBAHA.119.312951
George Thanassoulis, Catherine Y Campbell, David S Owens. Genetic associations with valvular calcification and aortic stenosis DOI: 10.1056/NEJMoa1109034
Pia R Kamstrup, Anne Tybjærg-Hansen, Børge G Nordestgaard. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population DOI: 10.1016/j.jacc.2013.09.038
Benoit J Arsenault , S Matthijs Boekholdt , Marie-Pierre Dubé i wsp. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort DOI: 10.1161/CIRCGENETICS.113.000400
R Vongpromek , S Bos , G-J R Ten Kate, R Yahya i wsp. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia DOI: 10.1111/joim.12335
Romain Capoulade, Kwan L Chan, Calvin Yeang i wsp. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis DOI: 10.1016/j.jacc.2015.07.020
Anne Langsted, Børge G Nordestgaard, Marianne Benn i wsp. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis DOI: 10.1210/jc.2016-1206
Benjamin J Cairns, Sean Coffey, Ruth C Travis i wsp. A Replicated, Genome-Wide Significant Association of Aortic Stenosis With a Genetic Variant for Lipoprotein(a): Meta-Analysis of Published and Novel Data DOI: 10.1161/CIRCULATIONAHA.116.026103
Hao Yu Chen, Line Dufresne, Hannah Burr i wsp. Association of LPA Variants With Aortic Stenosis: A Large-Scale Study Using Diagnostic and Procedural Codes From Electronic Health Records DOI: 10.1001/jamacardio.2017.4266
Nicolas Perrot, Sébastien Thériault, Christian Dina i wsp. Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification DOI: 10.1001/jamacardio.2019.1581
Jing Cao, Brian T Steffen, Matthew Budoff, Wendy S Post i wsp. Lipoprotein(a) Levels Are Associated With Subclinical Calcific Aortic Valve Disease in White and Black Individuals: The Multi-Ethnic Study of Atherosclerosis DOI: 10.1161/ATVBAHA.115.306683
Despres AA, Perrot N, PoulinA, TastetL, ShenM, ChenHYet al. Lipoprotein(a), oxidized phospholipids, and aortic valve microcalcification assessed by 18F-sodium fluoride positron emission tomography and computed tomography. CJC Open, 2019;1:131–140
Yannick Kaiser, Nick S Nurmohamed, Jeffrey Kroon i wsp. Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis DOI: 10.1136/heartjnl-2021-319804
Kang H Zheng, Sotirios Tsimikas, Tania Pawade i wsp. Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis DOI: 10.1016/j.jacc.2019.01.070
Konstantinos N. Aronis, Di Zhao, Ron C. Hoogeveen, Alvaro Alonso i wsp. Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study, https://doi.org/10.1161/JAHA.117.007372
Yuesong Pan, Hao Li, Yilong Wang, Xia Meng , Yongjun Wang. Causal Effect of Lp(a) [Lipoprotein(a)] Level on Ischemic Stroke and Alzheimer Disease: A Mendelian Randomization Study DOI: 10.1161/STROKEAHA.119.026872
Markus Arnold, Juliane Schweizer, Christos T Nakas i wsp. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study DOI: 10.1093/eurheartj/ehab081
Børge G Nordestgaard, Anne Langsted. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology DOI: 10.1194/jlr.R071233
Alexander H Nave, Kristin S Lange, Christopher O Leonards i wsp. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis DOI: 10.1016/j.atherosclerosis.2015.08.021
Michael B Boffa. Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis DOI: 10.1016/j.atherosclerosis.2022.04.009
Børge G Nordestgaard, Anne Langsted. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology DOI: 10.1194/jlr.R071233
Samia Mora, Pia R Kamstrup, Nader Rifai, Børge G Nordestgaard, Julie E Buring, Paul M Ridker Lipoprotein(a) and risk of type 2 diabetes DOI: 10.1373/clinchem.2010.146779
Lin Ding, An Song, Meng Dai, Min Xu, Wanwan Sun, Baihui Xu , Jichao Sun i wsp. Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population DOI: 10.1194/jlr.P049015
Michelle L O'Donoghue. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk i wsp. DOI: 10.1161/CIRCULATIONAHA.118.037184
Michael Szarek i wsp. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial DOI: 10.1093/eurheartj/ehaa649
William E Boden, Jeffrey L Probstfield, Todd Anderson, Bernard R Chaitman, Patrice Desvignes-Nickens i wsp. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy AIM-HIGH Investigators; DOI: 10.1056/NEJMoa1107579
Martin J Landray, Richard Haynes, Jemma C Hopewell, Sarah Parish i wsp. Effects of extended-release niacin with laropiprant in high-risk patients HPS2-THRIVE Collaborative Group; DOI: 10.1056/NEJMoa1300955
Daniel I Chasman , Dov Shiffman, Robert Y L Zee i wsp. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy DOI: 10.1016/j.atherosclerosis.2008.07.019
Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis Sotirios Tsimikas DOI: 10.1161/CIRCRESAHA.118.313864
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease Michelle L. O’Donoghue, M.D., M.P.H., Michelle L O'Donoghue, Robert S Rosenson, Baris Gencer, J Antonio G López , Norman E Lepor , Seth J Baum , Elmer Stout , Daniel Gaudet, Beat Knusel , Julia F Kuder, Xinhui Ran, Sabina A Murphy, Huei Wang, You Wu , Helina Kassahun, Marc S Sabatine ; OCEAN(a)-DOSE Trial Investigators
Calvin Yeang, Ewa Karwatowska-Prokopczuk, Fei Su i wsp. Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol DOI: 10.1016/j.jacc.2021.12.032
Sotirios Tsimikas , Ewa Karwatowska-Prokopczuk, Ioanna Gouni-Berthold Lipoprotein(a) Reduction in Persons with Cardiovascular Disease AKCEA-APO(a)-LRx Study Investigators DOI: 10.1056/NEJMoa1905239
Maciej Banach, Paweł Burchardt, Krzysztof Chlebus i wsp. Wytyczne PTL/KLRwP/PTK/PTDL/PTD/PTNT Diagnostyki i Leczenia Zaburzeń Lipidowych w Polsce 2021
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Monika Maj-Dziedzic, Anna Brzozowska, Marcelina Sikora, Marta Zarzycka, Ines Plewniok, Jeremiasz Dubiel, Adrian Maj, Greta Śmietana, Martyna Warno, Wiktor Kozik
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 514
Number of citations: 0
